Dear Colleagues,

This Special Issue is a continuation of our previous Issue, “Female Malignancies and Immunotherapy: What’s New?”

(https://0-www-mdpi-com.brum.beds.ac.uk/journal/cancers/special_issues/Malignancies_Immunotherapy)

Current emerging therapies for solid tumors include various immunotherapeutic approaches, such as immune-checkpoint inhibitors (ICIs), which have gained considerable attention because of their impressive treatment outcomes in different tumor types. Unfortunately, benefits have been seen only in a small percentage of patients with solid tumors. For this reason, it is necessary to improve our knowledge on immune checkpoints (ICs) and on the tumor microenvironment.

In the cancer treatment context, T cells have always been considered primarily responsible for the beneficial effect of immunotherapy. However, NK cells are also now seen as a promising cancer immunotherapy tool due to their ability to kill malignant cells without toxicity towards healthy cells. However, cancers develop escape strategies to alter immune cells’ anti-tumor activity.

Among existing cancers, female malignancies present challenges in terms of diagnosis and the efficacy of clinical approaches. Indeed, female tumors are often characterized by an immunosuppressive tumor environment, able to resist not only immune system attack, but also advanced immunotherapeutic approaches.

The goal of this Special Issue, “Female Malignancies and Immunotherapy: What’s New? 2.0”, is to contribute to dissecting the molecular and cellular immunological mechanisms involved in female malignancies’ progression and metastasis. This information will provide new insights that are crucial for the development of new immunotherapeutic strategies and for the improvement of combination strategies in the patient-specific treatment of female cancers.

Dr. Silvia Pesce
Dr. Piero Fregatti
Dr. Valerio Gaetano Vellone
Dr. Emanuela Marcenaro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• breast cancer
• ovarian cancer
• cervical cancer
• natural killer cells
• immunotherapy
• cancer immunology